Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition
Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition
Phibro Animal Health Corporation (NASDAQ: PAHC) is on bullish trend during the current market trading today, marking a substantial increase of 29.41% to reach a valuation of $16.47. This upswing in PAHC stock follows an asset acquisition agreement.
在今天的市场交易中，Phibro动物健康公司（纳斯达克股票代码：PAHC）处于看涨趋势，大幅上涨了29.41％，估值达到16.47美元。PAHC股票的上涨是在达成资产收购协议之后出现的。
Phibro Animal Health (PAHC) announced today that it and Zoetis Inc. (NYSE: ZTS) have entered into a final agreement. PAHC will pay $350 million, subject to normal closing adjustments, to acquire Zoetis' medicated feed additive (MFA) product array, certain water soluble products, and related assets.
Phibro Animal Health（PAHC）今天宣布，它与Zoetis公司（纽约证券交易所代码：ZTS）已签订最终协议。PAHC将支付3.5亿美元，以收购Zoetis的药用饲料添加剂（MFA）产品系列、某些水溶性产品和相关资产，但须视正常收盘调整而定。
It is anticipated that this deal would close in the second half of 2024. Zoetis and Phibro Animal Health both have a long history of commitment to the production animal health industry. The product assortment that was bought generated around $400 million in revenue in 2023 and consists of more than 37 product variants that are sold in almost 80 different countries.
预计这笔交易将在2024年下半年完成。Zoetis和Phibro Animal Health都对生产性动物健康行业有着悠久的承诺。购买的产品类别在2023年创造了约4亿美元的收入，包括37多种产品变体，在近80个不同的国家销售。
Moreover, the agreement encompasses six manufacturing facilities, with four situated in the U.S., one in Italy, and one in China. It is foreseen that over 300 Zoetis employees involved in manufacturing, distribution, and commercial operations will transition to Phibro Animal Health.
此外，该协议包括六个制造工厂，其中四个位于美国，一个位于意大利，一个位于中国。预计参与制造、分销和商业运营的300多名Zoetis员工将过渡到Phibro Animal Health。
This transaction underscores Zoetis' disciplined approach to capital allocation, prioritizing investments in animal health, productivity, and sustainability solutions. Through this divestiture, Zoetis can redirect its livestock investments towards other solutions, encompassing vaccine, biologic, and genetic programs.
该交易凸显了Zoetis严格的资本配置方针，优先投资于动物健康、生产力和可持续发展解决方案。通过这种剥离，Zoetis可以将其牲畜投资转向其他解决方案，包括疫苗、生物和遗传计划。
Zoetis' robust portfolio of MFA and water soluble products spanning cattle, swine, and poultry will complement and broaden Phibro Animal Health's species and product portfolios, aiding customers in meeting the most stringent standards of animal welfare, disease prevention, and nutritional enhancement.
Zoetis强大的MFA和水溶性产品组合，涵盖牛、猪和家禽，将补充和扩大Phibro Animal Health的物种和产品组合，帮助客户满足最严格的动物福利、疾病预防和营养增强标准。
If the acquisition's effects were taken into account, Phibro Animal Health would have had revenues of about $1.4 billion during the previous year. The acquisition is set to be primarily financed through debt, with Phibro Animal Health securing financing commitments from several key banking partners.
如果将此次收购的影响考虑在内，Phibro Animal Health上一年的收入将达到约14亿美元。此次收购将主要通过债务融资，Phibro Animal Health将获得多个主要银行合作伙伴的融资承诺。
Over an extensive timeframe, Zoetis has established a valuable, top-tier, and dependable source of medicated feed additives worldwide. The asset acquisition will serve to enrich, diversify, and expand PAHC's global portfolio.
在很长的时间内，Zoetis已经在全球范围内建立了宝贵、一流和可靠的药用饲料添加剂来源。此次资产收购将有助于丰富、多元化和扩大PAHC的全球投资组合。